|
COPYRIGHT 2002 Ingram Investment Ltd.
M2 PRESSWIRE-17 December 2002-Research and Markets Ltd: Proteomics: Analysis of Selected Emerging Technologies(C)1994-2002 M2 COMMUNICATIONS LTD
RDATE:12162002
The first of Cambridge Healthtech Institute`s Summit Reports takes a close look at some of the key technologies that promise to take proteomics into the realm of automation and high throughput analysis.
Although automation is being applied to what has traditionally been the workhorse of protein analysis - 2D gel electrophoresis - many limitations remain as to the speed, sensitivity and reproducibility of this decades old method.
In this report, the insight and experience of several pharmaceutical industry leaders on emerging technologies are captured from a 2000 Proteomics conference organized by Cambridge Healthtech Institute.
Here they present some of the important tools, such as microarrays, phage display and structural analysis that will hopefully bring us closer to a full account of the human proteome.
Contributors include major players in the proteomics market: Ciphergen, Amersham Pharmacia Biotech, Molecular Staging, Morphochem, Phylos, Dyax and the European Molecular Biological Laboratory.
Key issues discussed include:
The impact of automation on proteomics Consensus rules for protein-protein interactions and their implication for drug design Protein chips and related, enabling technologies Methods that impart amplification on proteins: phage display and Profusion technologies Post-proteomic technologies such as automated live cell assays Recent collaborative activity and technology position of all major players in proteomics
About the...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
